Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX®, the only immunotherapy for Stage II colon cancer.
The ancients used the Ouroboros, the image of the snake consuming its own tail, to symbolize immortality and perfection. At Vaccinogen, we chose it as part of our logo because our approach to preventing the return of cancer – and extending the lives of the thousands of patients we expect to use OncoVAX® – may be almost perfect. Like the snake consuming itself, our approach involves using the patient’s own cancer cells to prevent the disease from recurring.
A key characteristic of cancer is that, because it is a mutation of the body’s own cells, it does not trigger the natural resistance that humans have to other diseases. Our OncoVAX® vaccine, the only product of its kind, actually conditions the body to fight its own cancer. As a result, our approach has none of the pain, disfigurement and side effects associated with other methods.
Although we are dedicated to preventing the return of cancer in many forms, OncoVAX® targets colon cancer, one of the most common forms of cancer related deaths. This vaccine has demonstrated its effectiveness and safety in early trials and is on the brink of initial European sales, as authorizations permit.
We believe our work on the development of immunotherapy products for the treatment of solid tumors and on commercialization of autologous tumor vaccine products meets a vast unmet medical need.
We already have the manufacturing capability to produce OncoVAX® commercially as well as a strong novel patent portfolio to protect it and our other platforms. We have developed other programs in both active specific immunotherapy (vaccines) and passive specific immunotherapy (fully human monoclonal antibodies).
Vaccinogen is also focused on discovering, developing and manufacturing fully human monoclonal antibodies for human clinical use. Its HumaSPECT antibody was one of the first to be widely approved for any clinical use worldwide. We are developing other products based on pioneering work in colon carcinoma, renal carcinoma and melanoma.
In sum, we believe our work on the development of immunotherapy products for the treatment of solid tumors and on commercialization of autologous tumor vaccine products meets a vast unmet medical need. It could dramatically change cancer treatment protocols and create a significant global market for these products.